Targeted Nanoparticle Therapy for Myeloma

A KaLwRij myeloma mouse model was used as described (32 (link)). KaLwRij mice were inoculated intravenously with 1 × 10⁶ 5TGM1 cells and distributed into six groups of 6 to 8 mice, and treated intravenously (a) nontargeted (NT) or targeted (T), (b) drug-bearing (D) or no-drug (ND) PFC or micelle NPs. The following treatment cohorts were studied: (i) ND/NT 200 nm PFC NP; (ii) T/ND 200 nm PFC NP; (iii) T/D 200 nm PFC NP; (iv) NT/ND 20 nm micelles; (v) T/ND 20 nm micelles, and (vi) T/D 20 nm micelles. 5TGM1 cells were injected via tail vein on day 0. NPs were administered by tail vein injection on days 3, 5, 7, 10, 12, and 14 with 50 μL of MI1 (0.145 mg/mL) per mouse. Sera were collected on day 17, diluted 1:2 in PBS, and analyzed by serum protein electrophoresis (SPEP) on a QuickGel Chamber apparatus using precasted QuickGels (Helena Laboratories) according to the manufacturer's instruction. Densitometric analysis of the SPEP traces was performed using the clinically certified Helena QuickScan 2000 workstation, allowing a precise quantification of the various serum fractions, including the measurements of gamma/albumin ratio.